@article{15dc0f2009154666a2c30da1a44724ae,
title = "Immunotherapy for Colorectal Cancer",
keywords = "Checkpoint inhibitor, Colorectal cancer, Immune checkpoint blockade, Immunotherapy, PD-1, PD-L1, Tumor mutation burden",
author = "Reetu Mukherji and Weinberg, {Benjamin A.} and Pedersen, {Katrina S.}",
note = "Funding Information: R. Mukherji has nothing to disclose. B.A. Weinberg discloses advisory boards for Taiho, Bayer; speakers bureau for Taiho, Bayer, Daiichi Sankyo, AstraZeneca, Lilly, Sirtex, and HalioDx; consultant for Novartis; and research support from Ipsen. K.S. Pedersen disclosed advisory boards for Array, Bayer, Novartis, and Pfizer; consultant for Pfizer and UpToDate; research support (institutional) from AbbVie, Arcus, Array, BioLineRx, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, MedImmune, Merck, Natera, Nouscom, Novartis, Pfizer, Pierre Fabre, Rafael, Roche/Genentech, and Sumitomo Dainippon.",
year = "2022",
month = jun,
doi = "10.1016/j.hoc.2022.02.010",
language = "English",
volume = "36",
pages = "603--626",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
number = "3",
}